Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 9, 2026, 1:46 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 7,508 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Lymphoproliferative Malignancies Clear all
Terminated Phase 2 Interventional Results available

Rituximab, Temozolomide, and Methylprednisolone in Treating Patients With Recurrent Primary CNS Non-Hodgkin's Lymphoma

NCT00248534
View directory record Official record
Conditions
Lymphoma
Interventions
rituximab, methylprednisolone, temozolomide
Biological · Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 120 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
7
States / cities
San Francisco, California • Boston, Massachusetts • Durham, North Carolina + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2018 · Synced Oct 9, 2026, 1:46 PM EDT
Active, not recruiting Phase 1 Interventional

Study of ABBV-383 Assessing Adverse Events and Clinical Activity With Subcutaneous (SC) Injection in Adult Participants With Relapsed or Refractory Multiple Myeloma

NCT06223516
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Subcutaneous (SC) Etentamig, Intravenous (IV) Etentamig
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
7
States / cities
Phoenix, Arizona • Jacksonville, Florida • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Oct 9, 2026, 1:46 PM EDT
Terminated Phase 1 Interventional

Intentional Rejection of the Donor Graft Using Recipient Leukocyte Infusion(s) Following Nonmyeloablative Allogeneic Stem Cell Transplant

NCT00909948
View directory record Official record
Conditions
Non Hodgkin's Lymphoma, Hodgkin Disease, Multiple Myeloma
Interventions
Fludarabine and total body irradiation, Total body irradiation
Other · Radiation
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 29, 2018 · Synced Oct 9, 2026, 1:46 PM EDT
Completed Phase 1 Interventional

Temsirolimus, Dexamethasone, Mitoxantrone Hydrochloride, Vincristine Sulfate, and Pegaspargase in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma

NCT01403415
View directory record Official record
Conditions
Childhood B Acute Lymphoblastic Leukemia, Childhood T Acute Lymphoblastic Leukemia, Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Lymphoblastic Lymphoma
Interventions
Dexamethasone, Laboratory Biomarker Analysis, Methotrexate, Mitoxantrone Hydrochloride, Pegaspargase, Pharmacological Study, Temsirolimus, Vincristine Sulfate
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Year to 21 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
30
States / cities
Birmingham, Alabama • Phoenix, Arizona • Orange, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2015 · Synced Oct 9, 2026, 1:46 PM EDT
Completed Phase 1 Interventional

Study of Carfilzomib and Vorinostat for Relapsed or Refractory Lymphoma

NCT01276717
View directory record Official record
Conditions
Lymphoma
Interventions
Drug: Carfilzomib, Vorinostat
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
2
States / cities
Rochester, New York • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 3, 2015 · Synced Oct 9, 2026, 1:46 PM EDT
Active, not recruiting Phase 3 Interventional

Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma

NCT05371093
View directory record Official record
Conditions
Relapsed/Refractory Follicular Lymphoma
Interventions
Axicabtagene Ciloleucel, Cyclophosphamide, Fludarabine, Lenalidomide, Rituximab, Doxorubicin, Vincristine, Prednisone, Bendamustine
Biological · Drug
Lead sponsor
Kite, A Gilead Company
Industry
Eligibility
18 Years and older
Enrollment
231 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
12
States / cities
Duarte, California • Stanford, California • Tampa, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Oct 9, 2026, 1:46 PM EDT
Completed Phase 1Phase 2 Interventional

Controlled Trial of Valacyclovir in Infectious Mononucleosis

NCT00274404
View directory record Official record
Conditions
Infectious Mononucleosis
Interventions
valacyclovir
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 27, 2011 · Synced Oct 9, 2026, 1:46 PM EDT
Completed Phase 1 Interventional

A Safety and Tolerability Study of Clofarabine, Etoposide, Cyclophosphamide, PEG-asparaginase, and Vincristine in Pediatric Acute Lymphoblastic Leukemia (ALL)

NCT00991133
View directory record Official record
Conditions
Lymphoblastic Leukemia, Acute, Childhood
Interventions
Clofarabine incorporated into a 5-drug regimen
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
1 Year to 30 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
6
States / cities
Los Angeles, California • Aurora, Colorado • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2015 · Synced Oct 9, 2026, 1:46 PM EDT
Recruiting Early Phase 1 Interventional

Combining Topical Imiquimod With Local Radiotherapy for Treatment of Mycosis Fungoides

NCT05838599
View directory record Official record
Conditions
Mycosis Fungoides
Interventions
Imiquimod, Radiation Therapy
Drug · Radiation
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 90 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 9, 2026, 1:46 PM EDT
Terminated Phase 1 Interventional Results available

T-cell Receptor α/β Depleted Donor Lymphocyte Infusion

NCT05350163
View directory record Official record
Conditions
Lymphoid Leukemia, Acute, Myeloid Malignancy, Plasma Cell Tumor
Interventions
T-cell Receptor α/β Depleted Donor Lymphocyte Infusions
Biological
Lead sponsor
Guenther Koehne
Other
Eligibility
18 Years to 74 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 10, 2024 · Synced Oct 9, 2026, 1:46 PM EDT
Completed Phase 2 Interventional Results available

Bortezomib and Dexamethasone Followed by High-Dose Melphalan and Stem Cell Transplantation for Primary (AL) Amyloidosis

NCT01083316
View directory record Official record
Conditions
Amyloidosis
Interventions
Bortezomib, Dexamethasone, Melphalan
Drug
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 25, 2020 · Synced Oct 9, 2026, 1:46 PM EDT
Not listed Phase 2Phase 3 Interventional

Monoclonal Antibodies in Detecting Residual Disease in Patients Who Have Been Treated for Non-Hodgkin's Lymphoma

NCT00003338
View directory record Official record
Conditions
Lymphoma
Interventions
immunoscintigraphy, technetium Tc 99m epratuzumab
Procedure · Radiation
Lead sponsor
Gilead Sciences
Industry
Eligibility
16 Years to 120 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
4
States / cities
Los Angeles, California • Baltimore, Maryland • Cuyahoga Falls, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2021 · Synced Oct 9, 2026, 1:46 PM EDT
Terminated Phase 2 Interventional Results available

Fludarabine, Velcade and Rituximab for Relapsed or Refractory Follicular Non-Hodgkin Lymphoma

NCT01186458
View directory record Official record
Conditions
Lymphoma, Non-Hodgkin
Interventions
Fludarabine, Velcade, Rituximab
Drug
Lead sponsor
Hoosier Cancer Research Network
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
11
States / cities
Bloomington, Indiana • Fort Wayne, Indiana • Indianapolis, Indiana + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2016 · Synced Oct 9, 2026, 1:46 PM EDT
Completed Phase 2 Interventional

Safety and Activity of SDX-105 (Bendamustine) in Patients With Rituximab Refractory Non-Hodgkin's Lymphoma

NCT00069758
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma
Interventions
SDX-105
Drug
Lead sponsor
Cephalon
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
13
States / cities
Birmingham, Alabama • Palm Springs, California • Vista, California + 10 more
Source: ClinicalTrials.gov public record
Updated May 9, 2014 · Synced Oct 9, 2026, 1:46 PM EDT
Completed Phase 1 Interventional

A Phase I, Dose-Escalation Study to Assess the Safety and Biological Activity of Recombinant Human Interleukin-18

NCT00500058
View directory record Official record
Conditions
Lymphoma, Non-Hodgkin
Interventions
SB-485232, Rituximab
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
2
States / cities
Chicago, Illinois • Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jul 26, 2017 · Synced Oct 9, 2026, 1:46 PM EDT
Terminated Phase 2 Interventional Results available

Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacodynamics of Entospletinib in Adults With Relapsed or Refractory Hematologic Malignancies

NCT01799889
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Diffuse Large B-cell Lymphoma, Non-FL Indolent Non-Hodgkin's Lymphoma, Follicular Lymphoma
Interventions
Entospletinib MM, Entospletinib SDD
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
326 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
46
States / cities
Birmingham, Alabama • Tucson, Arizona • Duarte, California + 42 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2020 · Synced Oct 9, 2026, 1:46 PM EDT
Active, not recruiting Phase 1 Interventional

CD19 Chimeric Receptor Expressing T Lymphocytes In B-Cell Non Hodgkin's Lymphoma, ALL & CLL

NCT00586391
View directory record Official record
Conditions
B Cell Lymphoma, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia
Interventions
CD19CAR-28-zeta T cells, Ipilimumab
Genetic · Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Not listed
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2029
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 9, 2026, 1:46 PM EDT
Completed Phase 1Phase 2 Interventional

Monoclonal Antibody Therapy in Treating Patients With Lymphoma or Leukemia

NCT00003874
View directory record Official record
Conditions
Leukemia, Lymphoma
Interventions
monoclonal antibody CD19, monoclonal antibody CD20, in vitro-treated peripheral blood stem cell transplantation
Biological · Procedure
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Up to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2001
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 29, 2011 · Synced Oct 9, 2026, 1:46 PM EDT
Completed Phase 2 Interventional Results available

Brentuximab Vedotin Plus AVD in Limited-stage Hodgkin Lymphoma

NCT01534078
View directory record Official record
Conditions
Hodgkin Lymphoma
Interventions
Brentuximab Vedotin, Adriamycin, vinblastine, and dacarbazine
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
4
States / cities
Tampa, Florida • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 20, 2018 · Synced Oct 9, 2026, 1:46 PM EDT
Completed Phase 3 Interventional Results available

A Study of Oral Ixazomib Citrate (MLN9708) Maintenance Therapy in Participants With Multiple Myeloma Following Autologous Stem Cell Transplant

NCT02181413
View directory record Official record
Conditions
Multiple Myeloma, Autologous Stem Cell Transplant
Interventions
Ixazomib Citrate, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
656 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
6
States / cities
Little Rock, Arkansas • Rochester, Minnesota • The Bronx, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2024 · Synced Oct 9, 2026, 1:46 PM EDT
Completed Phase 1 Interventional

Combination Therapy of Lenalidomide/Bortezomib/Dexamethasone and Panobinostat in Transplant Eligible New Diagnosed Multiple Myeloma (MM) Patients

NCT01440582
View directory record Official record
Conditions
Myeloma
Interventions
Panobinostat, Bortezomib, Lenalidomide, Dexamethasone, Symptom Questionnaire
Drug · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 4, 2019 · Synced Oct 9, 2026, 1:46 PM EDT
Completed Not applicable Interventional

Music Therapy to Ease Pain and Emotional Distress in Patients With Hematologic Cancer Who Are Undergoing High-Dose Therapy and Stem Cell Transplantation

NCT00014482
View directory record Official record
Conditions
Anxiety Disorder, Chronic Myeloproliferative Disorders, Depression, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Pain
Interventions
pain therapy, psychosocial assessment and care
Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 18, 2013 · Synced Oct 9, 2026, 1:46 PM EDT
Recruiting Phase 2 Interventional

Ruxolitinib for the Treatment of T-Cell Large Granular Lymphocytic Leukemia

NCT05592015
View directory record Official record
Conditions
T-Cell Large Granular Lymphocyte Leukemia
Interventions
Ruxolitinib
Drug
Lead sponsor
Jonathan Brammer
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
3
States / cities
Boston, Massachusetts • New York, New York • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 9, 2026, 1:46 PM EDT
Active, not recruiting Phase 1 Interventional

Adding Ruxolitinib to a Combination of Dasatinib Plus Dexamethasone in Remission Induction Therapy in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Patients Aged 40 Years or Older

NCT02494882
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia
Interventions
Ruxolitinib, Dasatinib, Dexamethasone
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
40 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 9, 2026, 1:46 PM EDT